Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

Life Molecular Imaging announces presentation of new research results at the European Association of Nuclear Medicine 2019 Annual Meeting

13. Oct 201913. Oct 2019lifemolecular

Click to read more: Research presented provides insights into LMI compounds comprising Neuraceq (florbetaben 18F), PI-2620, RM2, GP1 and FSPG.

Related

Post navigation

← Life Molecular Imaging started recruitment for longitudinal Phase 2 Study with the Tau tracer PI-2620
Life Molecular Imaging and Positron Pharma Announce a Strategic Partnership for Manufacturing and Distribution of PI-2620 in Chile →
© Copyright 2018 Life Molecular Imaging
Imprint / Data protection
Contact
Scroll to Top
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection